Bio-Connect
FACS analysis of HEK293T cells transfected with either XRCC1 plasmid(Red) or empty vector control plasmid(Blue) using GTX83411 XRCC1 antibody [2D8].
FACS analysis of HEK293T cells transfected with either XRCC1 plasmid(Red) or empty vector control plasmid(Blue) using GTX83411 XRCC1 antibody [2D8].
FACS analysis of HEK293T cells transfected with either XRCC1 plasmid(Red) or empty vector control plasmid(Blue) using GTX83411 XRCC1 antibody [2D8].

XRCC1 antibody [2D8]

GTX83411
GeneTex
ApplicationsFlow Cytometry, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetXRCC1
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    XRCC1 antibody [2D8]
  • Delivery Days Customer
    9
  • Application Supplier Note
    WB: 1:1000. IHC-P: 1:50. FACS: 1:100. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    Flow Cytometry, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    2D8
  • Concentration
    0.57 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID7515
  • Target name
    XRCC1
  • Target description
    X-ray repair cross complementing 1
  • Target synonyms
    RCC, SCAR26, DNA repair protein XRCC1, X-ray repair complementing defective repair in Chinese hamster cells 1, X-ray repair cross-complementing protein 1
  • Host
    Mouse
  • Isotype
    IgG1
  • Protein IDP18887
  • Protein Name
    DNA repair protein XRCC1
  • Scientific Description
    Corrects defective DNA strand-break repair and sister chromatid exchange following treatment with ionizing radiation and alkylating agents.
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • Wang YY, Fang PT, Su CW, et al. Excision repair cross-complementing group 2 upregulation is a potential predictive biomarker for oral squamous cell carcinoma recurrence. Oncol Lett. 2021,21(6):450. doi: 10.3892/ol.2021.12711
    Read this paper